<div id="readability-page-1"><p>TD Cowen analyst Joseph Thome has maintained their bullish  stance on <span>DRUG</span> stock, giving a Buy rating today.</p><h3>Valentine's Day Sale - 70% Off</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Joseph Thome has given his Buy rating due to a combination of factors tied to both clinical performance and valuation. He highlights that BMB-101 delivered stronger-than-expected seizure reductions in absence epilepsy and developmental and epileptic encephalopathies, with a safety profile in line with the 5-HT2C class, supporting the start of global registrational trials in 2026 and leading him to raise his peak sales assumptions materially in both indications.</p> <p>Thome also underscores the added upside from the Prader-Willi syndrome franchise, where a proof-of-concept study with BMB-101 and a planned Phase I for follow-on asset BMB-105 are designed to accelerate time to market while addressing unmet needs across appetite, weight, and behavioral domains. Coupled with a solid cash position and strong support from key opinion leaders, he views 2026 as a pivotal execution year and believes the current share price does not adequately reflect the company’s de-risked pipeline and expanded commercial potential, justifying his Buy recommendation.</p> <p>In another report released today, Robert W. Baird also maintained a Buy rating on the stock with a $126.00 price target.</p></div>

DRUG

SBIO

<p>TD Cowen analyst Joseph Thome has maintained a Buy rating on DRUG stock, citing strong clinical performance of BMB-101 in treating absence epilepsy and developmental and epileptic encephalopathies. He anticipates pivotal global trials in 2026 and has raised peak sales estimates. Thome also highlights potential in the Prader-Willi syndrome franchise and believes the current share price does not reflect the company's de-risked pipeline. Robert W. Baird also supports this with a Buy rating and a $126 price target.</p>

Tip Ranks

iShares Biotechnology ETF

Bright Minds Biosciences

ALPS Medical Breakthrough

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise